M Kathryn Fink, who works at Stryker Co. (NYSE: SYK) and holds the position of vice president there, sold 3,536 shares of the company’s stock on January 9. The purchasers paid an average price per share of $260 during the sale, bringing the total value of the transaction to $919,360. The vice president now owns 9,264 company shares, and the total value of those shares is $2,408,640 as a direct result of the transaction. You might find a filing that explains the transaction in greater detail on the Securities and Exchange Commission (SEC) website.
Just recently, Ms. Kathryn Fink completed the transaction(s) listed below:
The following are some examples of NASDAQ-traded common stocks:
The price of SYK had decreased by $5.00 by noon on Wednesday, bringing the current value to $258.81. It was reported that there were 1,590,456 transactions involving the company’s shares, which is significantly less than the average volume of 1,620,282 transactions. Because the company has a market value of $97.94 billion, a PE ratio of 40.25, a price-to-earnings-growth ratio of 2.91, and a beta value of 0.94, it is an attractive investment opportunity. In addition to this, the price-to-earnings growth ratio currently stands at 2.91. The moving average of the company’s stock price over the past fifty days is $236.33, and the moving average over the last 200 days is $220.08. Stryker Company’s share price has never been lower than $188.84 in the past year, while it has never been higher than $279.28. The lowest price it has ever been being $188.84. The debt-to-equity ratio comes in at 0.77, the current ratio at 2.04, and the quick ratio at 1.19. All of these figures are presented as percentages.
On Monday, October 31, Stryker’s most recent quarterly earnings report (NYSE: SYK) was made public for the investing community to see. Earnings per share for the quarter were reported to be $2.12 by the medical equipment manufacturer, which was $0.12 less than the consensus projection of $2.24. Stryker achieved a return on equity of 22.27%, while the company’s net margin came in at 13.69%. The quarterly sales for the company came in at $4.48 billion, which is significantly higher than the average forecast for the period, which was $4.46 billion. The company made a profit of $2.20 per share during the same period the year before, which was the same period. In comparison to the same period in the previous year, the third quarter saw a revenue increase of 7.7% for the company. According to projections made by industry analysts, Stryker Company is expected to generate earnings of $9.17 per share in 2018.
In addition, the business just recently announced a quarterly dividend scheduled to be paid out on January 31. On Friday, December 30, ” recorded ” investors will be eligible to receive a dividend payment of $0.75 per share. This payment will be made. As a direct result, the dividend yield is calculated to be 1.16%, and the annual payout amounts to $3. It increased to that amount from the previous dividend payment that Stryker made, which was $0.70 per quarter. The dividend will be withheld from shareholder accounts on Thursday, December 29. The annual dividend payout made by Stryker is calculated to be 46.66 percent of earnings.
In recent times, SYK has successfully obtained feedback from various research firms. The rating for Stryker was raised from “sector perform” to “outperform” in a research study conducted by the Royal Bank of Canada and made available for public consumption on Monday. In addition, the price target they had established for the company was increased from $240.00 to $284.00. In a report distributed on November 1, Canaccord Genuity Group lowered their price target on Stryker from $225.00 to $220.00 and changed it from a “buy” rating to a “hold” rating. According to the research findings, Stryker was given a rating of “hold” rather than the previous “buy” recommendation. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and raised their target price on the stock from $220.00 to $260.00 in a research report published on Friday, January 6. On November 4, StockNews.com changed its rating on Stryker stock from “hold” to “buy,” indicating that they now have a more bullish sentiment toward the company. Canaccord Genuity Group announced in a report released on Tuesday, November 1, that they would be decreasing their target price for Stryker from $225.00 to $220.00. The previous target price was set at $225.00. The recommendation that Stryker should be purchased was changed to a recommendation that it should be held instead. Six financial analysts suggest that the stock should be held in one’s portfolio, while thirteen others suggest that the stock should be purchased. According to the data from Bloomberg.com, the company is currently being given an average rating of “Moderate Buy,” The price target has been set at $260.68 on average.
Recently, institutional investors and hedge funds have increased the proportion of the company’s holdings that they own. This increase occurred simultaneously across multiple holdings. A new investment of $25,000 was made in Stryker by Align Wealth Management LLC during the final three months of the year 2018. In the last three months of 2018, Madden Securities Corporation opened a new position in Stryker that was estimated to be worth about $29,000. On behalf of Hazlett Burt & Watson Inc., a new investment in Stryker was purchased during the third quarter at approximately $41,000. EverSource Wealth Advisors LLC increased the amount of Stryker stock owned by 41.4 percent over the first three months of 2018. EverSource Wealth Advisors LLC now holds 164 shares of the medical technology company’s stock after making an additional purchase of 48 shares during the most recent reporting period. Based on the stock’s current price, EverSource Wealth Advisors LLC has a holding value of $44,000. Last but not least, during the second quarter, Total Clarity Wealth Management Inc. invested close to $44,000 to acquire an additional position in Stryker. Currently, 77.10% of the total number of shares in the company are owned by institutions.